Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).
Identifieur interne : 000185 ( Main/Exploration ); précédent : 000184; suivant : 000186Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).
Auteurs : Eric L. Altschuler [États-Unis] ; Richard E. Kast [États-Unis]Source :
- Medical hypotheses [ 1532-2777 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Betacoronavirus (MeSH), Chimiotaxie des leucocytes (effets des médicaments et des substances chimiques), Colchicine (administration et posologie), Colchicine (usage thérapeutique), Dapsone (administration et posologie), Dapsone (usage thérapeutique), Granulocytes neutrophiles (effets des médicaments et des substances chimiques), Humains (MeSH), Infections à coronavirus (complications), Interleukine-8 (physiologie), Olanzapine (administration et posologie), Olanzapine (usage thérapeutique), Pandémies (MeSH), Pneumopathie virale (complications).
- MESH :
- administration et posologie : Colchicine, Dapsone, Olanzapine.
- effets des médicaments et des substances chimiques : Chimiotaxie des leucocytes, Granulocytes neutrophiles.
- physiologie : Interleukine-8.
- usage thérapeutique : Colchicine, Dapsone, Olanzapine.
- complications : Adulte, Betacoronavirus, Humains, Infections à coronavirus, Pandémies, Pneumopathie virale.
English descriptors
- KwdEn :
- Adult (MeSH), Betacoronavirus (MeSH), COVID-19 (MeSH), Chemotaxis, Leukocyte (drug effects), Colchicine (administration & dosage), Colchicine (therapeutic use), Coronavirus Infections (complications), Dapsone (administration & dosage), Dapsone (therapeutic use), Humans (MeSH), Interleukin-8 (physiology), Neutrophils (drug effects), Olanzapine (administration & dosage), Olanzapine (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (complications), Respiratory Distress Syndrome (drug therapy), Respiratory Distress Syndrome (etiology), SARS-CoV-2 (MeSH).
- MESH :
- chemical , administration & dosage : Colchicine, Dapsone, Olanzapine.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug effects : Chemotaxis, Leukocyte, Neutrophils.
- drug therapy : Respiratory Distress Syndrome.
- etiology : Respiratory Distress Syndrome.
- chemical , physiology : Interleukin-8.
- chemical , therapeutic use : Colchicine, Dapsone, Olanzapine.
- Adult, Betacoronavirus, COVID-19, Humans, Pandemics, SARS-CoV-2.
DOI: 10.1016/j.mehy.2020.109774
PubMed: 32344275
PubMed Central: PMC7177090
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).</title><author><name sortKey="Altschuler, Eric L" sort="Altschuler, Eric L" uniqKey="Altschuler E" first="Eric L" last="Altschuler">Eric L. Altschuler</name><affiliation wicri:level="2"><nlm:affiliation>Department of Physical Medicine and Rehabilitation, Metropolitan Hospital, New York, NY, USA. Electronic address: altschue@nychhc.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Physical Medicine and Rehabilitation, Metropolitan Hospital, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Kast, Richard E" sort="Kast, Richard E" uniqKey="Kast R" first="Richard E" last="Kast">Richard E. Kast</name><affiliation wicri:level="2"><nlm:affiliation>IIAIGC Study Center, 22 Church Street, Burlington, VT 05401, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>IIAIGC Study Center, 22 Church Street, Burlington, VT 05401</wicri:regionArea><placeName><region type="state">Vermont</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32344275</idno><idno type="pmid">32344275</idno><idno type="doi">10.1016/j.mehy.2020.109774</idno><idno type="pmc">PMC7177090</idno><idno type="wicri:Area/Main/Corpus">000232</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000232</idno><idno type="wicri:Area/Main/Curation">000232</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000232</idno><idno type="wicri:Area/Main/Exploration">000232</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).</title><author><name sortKey="Altschuler, Eric L" sort="Altschuler, Eric L" uniqKey="Altschuler E" first="Eric L" last="Altschuler">Eric L. Altschuler</name><affiliation wicri:level="2"><nlm:affiliation>Department of Physical Medicine and Rehabilitation, Metropolitan Hospital, New York, NY, USA. Electronic address: altschue@nychhc.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Physical Medicine and Rehabilitation, Metropolitan Hospital, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Kast, Richard E" sort="Kast, Richard E" uniqKey="Kast R" first="Richard E" last="Kast">Richard E. Kast</name><affiliation wicri:level="2"><nlm:affiliation>IIAIGC Study Center, 22 Church Street, Burlington, VT 05401, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>IIAIGC Study Center, 22 Church Street, Burlington, VT 05401</wicri:regionArea><placeName><region type="state">Vermont</region></placeName></affiliation></author></analytic><series><title level="j">Medical hypotheses</title><idno type="eISSN">1532-2777</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Chemotaxis, Leukocyte (drug effects)</term><term>Colchicine (administration & dosage)</term><term>Colchicine (therapeutic use)</term><term>Coronavirus Infections (complications)</term><term>Dapsone (administration & dosage)</term><term>Dapsone (therapeutic use)</term><term>Humans (MeSH)</term><term>Interleukin-8 (physiology)</term><term>Neutrophils (drug effects)</term><term>Olanzapine (administration & dosage)</term><term>Olanzapine (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Respiratory Distress Syndrome (drug therapy)</term><term>Respiratory Distress Syndrome (etiology)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>Chimiotaxie des leucocytes (effets des médicaments et des substances chimiques)</term><term>Colchicine (administration et posologie)</term><term>Colchicine (usage thérapeutique)</term><term>Dapsone (administration et posologie)</term><term>Dapsone (usage thérapeutique)</term><term>Granulocytes neutrophiles (effets des médicaments et des substances chimiques)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (complications)</term><term>Interleukine-8 (physiologie)</term><term>Olanzapine (administration et posologie)</term><term>Olanzapine (usage thérapeutique)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (complications)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Colchicine</term><term>Dapsone</term><term>Olanzapine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Colchicine</term><term>Dapsone</term><term>Olanzapine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Chemotaxis, Leukocyte</term><term>Neutrophils</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Respiratory Distress Syndrome</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Chimiotaxie des leucocytes</term><term>Granulocytes neutrophiles</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Respiratory Distress Syndrome</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Interleukine-8</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Interleukin-8</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Colchicine</term><term>Dapsone</term><term>Olanzapine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Colchicine</term><term>Dapsone</term><term>Olanzapine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Betacoronavirus</term><term>COVID-19</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="fr"><term>Adulte</term><term>Betacoronavirus</term><term>Humains</term><term>Infections à coronavirus</term><term>Pandémies</term><term>Pneumopathie virale</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32344275</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2777</ISSN><JournalIssue CitedMedium="Internet"><Volume>141</Volume><PubDate><Year>2020</Year><Month>08</Month></PubDate></JournalIssue><Title>Medical hypotheses</Title><ISOAbbreviation>Med Hypotheses</ISOAbbreviation></Journal><ArticleTitle>Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).</ArticleTitle><Pagination><MedlinePgn>109774</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0306-9877(20)30492-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mehy.2020.109774</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altschuler</LastName><ForeName>Eric L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Metropolitan Hospital, New York, NY, USA. Electronic address: altschue@nychhc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kast</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>IIAIGC Study Center, 22 Church Street, Burlington, VT 05401, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Hypotheses</MedlineTA><NlmUniqueID>7505668</NlmUniqueID><ISSNLinking>0306-9877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance></Chemical><Chemical><RegistryNumber>8W5C518302</RegistryNumber><NameOfSubstance UI="D003622">Dapsone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>SML2Y3J35T</RegistryNumber><NameOfSubstance UI="D003078">Colchicine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002634" MajorTopicYN="N">Chemotaxis, Leukocyte</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003078" MajorTopicYN="N">Colchicine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003622" MajorTopicYN="N">Dapsone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32344275</ArticleId><ArticleId IdType="pii">S0306-9877(20)30492-8</ArticleId><ArticleId IdType="doi">10.1016/j.mehy.2020.109774</ArticleId><ArticleId IdType="pmc">PMC7177090</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Vermont</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Altschuler, Eric L" sort="Altschuler, Eric L" uniqKey="Altschuler E" first="Eric L" last="Altschuler">Eric L. Altschuler</name></region><name sortKey="Kast, Richard E" sort="Kast, Richard E" uniqKey="Kast R" first="Richard E" last="Kast">Richard E. Kast</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Wicri/explor/CovidPublicV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000185 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000185 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Wicri
|area= CovidPublicV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32344275
|texte= Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32344275" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidPublicV1
| This area was generated with Dilib version V0.6.38. |  |